


Early Phase Oncology Expertise IQVIA Biotech Australia

Over the past decade, Australia has emerged as the leading destination for early phase oncology clinical trials

33% of early phase oncology studies in Australia are sponsored by Emerging Biotech



# **Our AUS Oncology Advisory Board**



#### Objective

Advise and make non-binding recommendations to IQVIA on protocols, IB, and study design



### Composition

6 Members who are key KOLs in the field of Oncology and specifically in Phase I studies



## Responsibilities

Expert advisory group and review committee which is independent from sponsors



#### IQVIA Medical Advisor

The IQVIA Medical Advisor and Site and Patient Networks Group are responsible for the servicing and running of this group



KOL: Key Opinion Leader

MSRG: Medical Safety
Review Group

# Early phase oncology EPON\* site network

This should take approx. 5 days to receive this feedback.

Oncology Advisory Board input will be prior to MSRG submission.

Established network of qualified private/public **Phase I Oncology sites** with FIH experience. This includes KOLs who are part of our **Oncology Advisory Board**.



Top 5 early phase oncology sites includes private phase I unit and public/private hospitals

- Oversight of clinical trial activities throughout the process
- Shorter start-up timelines (~3-4 months) from EC submission to CTN Acknowledgement.
- > 20 sites available for FIH/phase Ia and > 20 sites available for phase Ib studies
- CAGT\* study also can be conducted by selected sites

\*EPON: Early Phase Oncology Network, CAGT: Cell and Gene Therapy

